X4 Pharmaceuticals, Inc Balance Sheet
XFOR|6 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
X4 Pharmaceuticals, Inc had $290M in total assets and $22M in shareholders' equity as of FY2025. Total debt was $75M against $217M in cash, resulting in a $142M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $217.0M | $55.7M | $81.8M | $78.7M | $8.1M | $76.8M |
| Accounts Receivable | $573.0K | $0 | - | - | - | - |
| Current Assets | $261.6M | $112.2M | $128.7M | $87.9M | $83.3M | $35.1M |
| PP&E (Net) | $182.0K | $776.0K | $1.1M | $1.5M | $1.2M | $285.0K |
| Goodwill | $17.4M | $17.4M | $27.1M | $27.1M | $27.1M | - |
| Total Assets | $290.5M | $146.4M | $155.6M | $117.2M | $122.9M | $36.0M |
| Current Liabilities | $25.8M | $32.9M | $22.3M | $14.0M | $11.9M | $5.4M |
| Total Debt | $75.0M | $75.0M | $32.5M | $32.5M | $32.5M | $9.7M |
| Shareholders' Equity | $22.1M | $74.1M | $72.8M | $129.2M | -$77.1M | -$56.6M |